Why the study?
Risk factors for VTE recurrence/exacerbation or switching from a DOAC to another anticoagulant in patients with gynecologic cancer using DOACs have not been thoroughly elucidated.
In patients with gynecologic cancer on DOACs, clear cell carcinoma of the ovary, PE or proximal DVT, and high D-dimer levels are significant risk factors for VTE recurrence or the need to switch anticoagulants.
Answers are grounded in this paper and cite their sources.
Risk factors warrant caution but should not yet change DOAC practice in gynecologic cancer; leaves open need for prospective validation.
The risk factors for venous thromboembolism (VTE) recurrence/exacerbation or a change from a direct oral anticoagulant (DOAC) to another anticoagulant in patients with gynecologic cancer using DOACs have not been thoroughly elucidated. Here, we aimed to investigate the risk factors for a composite primary outcome, including VTE recurrence/exacerbation, or a change from a DOAC to another anticoagulant, in this population. A total of 63 patients were analyzed. Risk factors for a primary outcome within 2 years after DOAC initiation were investigated using multiple logistic regression analysis. Among the 63 patients, 10 developed a primary outcome. Clear cell carcinoma of the ovary (adjusted odds ratio (aOR), 18.9; 95% confidence interval (CI), 2.25-350.74), pulmonary embolism (PE) or proximal deep vein thrombosis without PE (aOR, 55.6; 95% CI, 3.29-11,774.66), and D-dimer levels in the third tertile (≥7.6 μg/dL) when VTE was first diagnosed (aOR, 6.37; 95% CI, 1.17-66.61) were associated with increased odds of a primary outcome in patients with gynecologic cancer using DOACs. Patients with one or more risk factors for a primary outcome require careful follow-up after DOAC initiation for the early recognition of treatment failure.
No takes yet. Share an insight, caveat, or question.
Shimizu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: